MedPath

EISAI CO

EISAI CO logo
🇯🇵Japan
Ownership
Public
Established
1941-12-06
Employees
11K
Market Cap
$12B
Website
http://www.eisai.co.jp

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Phase 2
Completed
Conditions
Functional Dyspepsia
Interventions
Drug: Placebo
First Posted Date
2010-03-18
Last Posted Date
2013-12-24
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
338
Registration Number
NCT01089543

A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-03-12
Last Posted Date
2013-05-13
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
16
Registration Number
NCT01085708

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-03-12
Last Posted Date
2013-05-13
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
16
Registration Number
NCT01085695

Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.

Phase 4
Completed
Conditions
End-Stage Renal Disease
Interventions
First Posted Date
2010-02-05
Last Posted Date
2013-05-14
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
6
Registration Number
NCT01063556

A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)

Phase 1
Completed
Conditions
Insomnia
Interventions
First Posted Date
2010-01-26
Last Posted Date
2013-02-12
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
42
Registration Number
NCT01055834

A Study of MORAb-003 in Patients With Solid Tumor

Phase 1
Completed
Conditions
Neoplasms
Solid Tumor
Interventions
First Posted Date
2010-01-14
Last Posted Date
2020-06-11
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
16
Registration Number
NCT01049061

A Study of MORAb-009 in Patients With Solid Tumor

Phase 1
Completed
Conditions
Cancer
Mesothelin-positive
Interventions
First Posted Date
2009-11-25
Last Posted Date
2016-01-21
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
17
Registration Number
NCT01018784

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2009-08-26
Last Posted Date
2021-12-17
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
253
Registration Number
NCT00965757

Study of E7389 for Advanced or Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2009-08-25
Last Posted Date
2013-08-15
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
81
Registration Number
NCT00965523

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2009-07-24
Last Posted Date
2019-02-01
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
66
Registration Number
NCT00946153
© Copyright 2025. All Rights Reserved by MedPath